

Thrombosis Management:

Simplified anticoagulation therapy with an oral, direct Factor Xa inhibitor for VTE prevention after THR and TKR

Chaired by Alexander GG Turpie and Reinhold Kreutz

Wednesday 25 March 2009, 11:30–13:00

Auditorium, Palacio de Congressos de Catalunya,
Barcelona, Spain

A satellite symposium sponsored by
Bayer Schering Pharma at the
14th Congress of the European Association
of Hospital Pharmacists
Barcelona, Spain
25–27 March 2009



Chairmen's Welcome

Dear Colleagues,

Anticoagulant prophylaxis after major orthopaedic surgery effectively reduces the incidence of venous thromboembolism (VTE). Symptomatic VTE can be fatal, or have disabling, chronic and costly consequences for patients' health.

We are delighted to host a satellite symposium at the Congress of the European Association of Hospital Pharmacists and invite you to attend presentations that illustrate how the novel, oral, direct, once-daily Factor Xa inhibitor rivaroxaban has the potential to simplify prophylaxis management in adult patients undergoing elective total hip and knee replacement (THR and TKR).

Professor Reinhold Kreutz will open the symposium by reviewing the pharmacological profile of rivaroxaban. Professor Sylvia Haas will then present the results of the extensive phase III RECORD clinical trial programme, which compared rivaroxaban and enoxaparin regimens for the prevention of VTE after THR and TKR. Finally, Professor Ben van Hout will explore the economic benefits that could potentially be achieved as a consequence of improved VTE prophylaxis.

We hope that you will be able to join us for what promises to be an interesting and informative session.

With kind regards,



Alexander GG Turpie



Reinhold Kreutz

Thrombosis Management:

Simplified anticoagulation therapy with an oral, direct Factor Xa inhibitor for VTE prevention after THR and TKR


Chaired by Alexander GG Turpie and Reinhold Kreutz

Wednesday 25 March 2009, 11:30–13:00

Auditorium, Palacio de Congressos de Catalunya, Barcelona, Spain

A satellite symposium sponsored by Bayer Schering Pharma at the EAHP Annual Congress 2009, 25–27 March 2009

- 11:30 **Welcome and introduction**
Alexander GG Turpie, Canada
-
- 11:40 **The pharmacological profile of rivaroxaban: A novel oral Factor Xa inhibitor**
Reinhold Kreutz, Germany
-
- 12:00 **Clinical evidence: Results from the RECORD clinical trial programme**
Sylvia Haas, Germany
-
- 12:20 **Economic implications of successful VTE prophylaxis**
Ben van Hout, The Netherlands
-
- 12:40 **Panel and audience discussion**
-
- 12:55 **Summary and close**
Reinhold Kreutz, Germany
-



Faculty

Chairs:

Dr Alexander GG Turpie

McMaster University and Hamilton Health Sciences
Hamilton, Ontario, Canada

Professor Reinhold Kreutz

Charité – Universitätsmedizin
Berlin, Germany

Speakers:

Professor Reinhold Kreutz

Charité – Universitätsmedizin
Berlin, Germany

Professor Sylvia Haas

Technical University
Munich, Germany

Professor Ben van Hout

Julius Center for Health Sciences and Primary Care
Utrecht University
Utrecht, The Netherlands

Sponsored by Bayer Schering Pharma

The marketing authorization for this product may vary from country to country. In Spain, rivaroxaban is currently not available.



Bayer HealthCare
Bayer Schering Pharma